STAT May 22, 2024
WASHINGTON — There are three FDA-approved drugs for treating alcohol use disorder. But a different medication, one frequently used off-label for the condition, could provide greater benefit to patients with alcohol-associated liver disease, a new study suggests.
The data, presented this week as an abstract at Digestive Disease Week in D.C., suggest anti-seizure gabapentinoids might be a simple and effective treatment for slowing the progression of alcohol-associated liver disease. Nearly 30 million adults in the United States have alcohol use disorder, according to the 2022 National Survey on Drug Use and Health.
The toll of alcohol-associated liver disease, including mortality, has been increasing for years, though exact estimates of ALD prevalence are hard to measure because many people...
Today's Sponsors
Today's Sponsor